EVENTS|NEWS|CONTACT|DONATE

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Read Our Newsletter

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Day

August 16, 2017

Social interaction affects cancer patients’ response to treatment

Social interaction in a cancer treatment setting can play a role in disease outcomes, potentially related to stress response. A new study...

Social Media

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Categories

Foundation News
Press Releases
Research News

Tags

adenocarcenoma advanced stage alcohol antibody biomarker blood chemoradiotherapy chemotherapy clinical trial clinical trials detection drugs endoscopy Epstein-Barr esophagogastric FDA gastrectomy gastric cancer registry gastroesophageal genes heartburn helicobacter pylori HER2 immunotherapy keytruda lonsurf metastatic nutrition peritoneal postoperative prevention proton pump inhibitor recovery recurrence research risk screening side-effects studies surgery survival treatment tumor virus women

Gastric Cancer Foundation

Tax ID 27-2978173

info@gastriccancer.org

PO Box 338
Millbrae, CA 94030

For Deliveries:
Gastric Cancer Foundation
501 Broadway, #338
Millbrae, CA 94030-1907

Site Map

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Social Feed

Gastric Cancer Foundation

1 week ago

Researchers at Cleveland Clinic developed a machine learning model that uses data from electronic health records to find patients most at risk for gastric cancer. The model incorporated data from 11,000 patients—including 567 with gastric cancer—and predicted gastric cancer risk with surprising accuracy. Researchers reported at the 2024 American College of Gastroenterology Annual Scientific Meeting. ... See MoreSee Less

Model Uses Machine Learning to Predict Patients at Risk of Gastric Cancer

consultqd.clevelandclinic.org

New research from Cleveland Clinic shows how a machine learning model could help clinicians better identify patients with a high risk for gastric cancer.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

Researchers at the MD Anderson Cancer Center discovered an enzyme, SMYD5, that fuels cancer growth by stimulating the production of certain proteins. They found that in mouse models of gastric cancer, targeting SMYD5 slowed down tumor growth and improved the efficacy of CAR-T cell therapy. ... See MoreSee Less

Enzyme discovery heralds new target for gastric cancer treatment

www.nature.com

Blocking enzyme SMYD5 inhibits tumour growth and primes lab models for combination therapy, offering hope for more effective treatments.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

In preclinical studies, combining the experimental drug pelcitoclax with chemotherapy was effective against HER2-positive gastric cancer. The drug is designed to overcome resistance to HER2-targeted drugs by binding to two tumor targets and inducing the death of cancer cells. ... See MoreSee Less

The novel BCL-2/BCL-XL inhibitor APG-1252-mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer - Acta Pharmacologica Sinica

www.nature.com

HER2-positive gastric cancer has a poor prognosis, with a high incidence of drug resistance and a lack of effective treatments for drug-resistant patients. The exploration of the mechanism of resistan...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

In clinical trials, the multi-kinase inhibitor Stivarga (regorafenib) produced an improvement in overall survival in patients with refractory advanced gastric cancer. The drug is currently on the market to treat colorectal cancer, gastrointestinal stromal tumors and hepatocellular carcinoma. Investigators believe the results show the drug improves quality of life and delays disease progression, and that it could prove effective in combination with chemotherapy and immunotherapy. ... See MoreSee Less

Regorafenib Provides Modest Survival Benefit in Refractory Advanced Gastric/GEJ Cancer

www.onclive.com

Regorafenib improved overall survival vs placebo in refractory advanced gastric or gastroesophageal junction cancer.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

3 weeks ago

When combined with best supportive care, the multi-kinase inhibitor regorafenib produced improvements in both overall survival and progression-free survival in a trial that included gastric cancer patients.www.oncologynewscentral.com/article/regorafenib-improves-survival-in-hard-to-treat-gastric-cancer ... See MoreSee Less

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Subscribe to Our Newsletter

We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.

© 2024 Gastric Cancer Foundation. All Rights Reserved.

EVENTS | NEWS | CONTACT | DONATE

X